New! Sign up for our free email newsletter.
Science News
from research organizations

Towards personalised medicine: One type of data is not enough

New computational method integrates multiple molecular data types to study the variability between patients in complex diseases

Date:
June 20, 2018
Source:
European Molecular Biology Laboratory - European Bioinformatics Institute
Summary:
To understand the biology of diseased organs researchers can use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types. A new computational method jointly analyses different types of molecular data and disentangles the sources of disease variability to guide personalised treatment.
Share:
FULL STORY

EMBL researchers have designed a computational method to jointly analyse multiple types of molecular data from patients in order to identify molecular signatures that distinguish individuals. The method is called Multi-Omics Factor Analysis (MOFA), and was published in Molecular Systems Biology today. MOFA could be particularly useful for understanding cancer development, improving diagnosis and suggesting new directions for personalised treatment.

The researchers tested their new method on multi-omics data collected from 200 leukemia patients. MOFA identified a series of factors that highlight the molecular variability between patients. This information could help researchers understand how cancer develops at an individual level. It could also help steer personalised treatment decisions.

"The big challenge in cancer is that each patient's disease is different from a molecular point of view and has a unique set of molecular features that have led to its development," explains Ricard Argelaguet, Predoctoral Fellow in the Stegle group at the European Bioinformatics Institute (EMBL-EBI). "Our method allows researchers to do something that couldn't be done before -- to easily integrate complex molecular data from DNA, RNA, methylation and more to build a tumour's molecular profile. Using these profiles, the method can also stratify patients into groups that may benefit from different types of treatment."

"Our objective was to come up with a method that could easily be used by clinical researchers, so we worked with colleagues from the field to understand their needs and challenges," continues Britta Velten, Predoctoral Fellow in the Huber group at EMBL Heidelberg. "We combined expertise from maths, statistics, machine learning, biology and clinical medicine to come up with a robust and practical method, which will hopefully help researchers in a clinical setting to improve cancer diagnosis and treatment."

In a second application, the researchers also used MOFA to analyse multi-omics data at single-cell resolution. They are currently working on further improving the method so that it can cope with even larger data sets and additional experimental designs.

What is multiomics data?

Multi-omics approaches integrate data from the genome, epigenome, transcriptome, metabolome, and other molecular data. These data types have different properties and dimensions and are difficult to integrate into a comprehensive analysis to build an individual's molecular profile.

However, by combining multiple molecular data types (multi-omics), researchers can identify biomarkers -- naturally occurring molecules, genes or molecular characteristics associated with a particular disease. Biomarkers are essential for clinical research and can be used to classify patients into different patient groups. By measuring biomarkers, we can understand a patient's disease better and estimate what kind of treatment they will respond to best.


Story Source:

Materials provided by European Molecular Biology Laboratory - European Bioinformatics Institute. Note: Content may be edited for style and length.


Journal Reference:

  1. Ricard Argelaguet, Britta Velten, Damien Arnol, Sascha Dietrich, Thorsten Zenz, John C Marioni, Florian Buettner, Wolfgang Huber, Oliver Stegle. Multi‐Omics Factor Analysis—a framework for unsupervised integration of multi‐omics data sets. Molecular Systems Biology, 2018; 14 (6): e8124 DOI: 10.15252/msb.20178124

Cite This Page:

European Molecular Biology Laboratory - European Bioinformatics Institute. "Towards personalised medicine: One type of data is not enough." ScienceDaily. ScienceDaily, 20 June 2018. <www.sciencedaily.com/releases/2018/06/180620150123.htm>.
European Molecular Biology Laboratory - European Bioinformatics Institute. (2018, June 20). Towards personalised medicine: One type of data is not enough. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2018/06/180620150123.htm
European Molecular Biology Laboratory - European Bioinformatics Institute. "Towards personalised medicine: One type of data is not enough." ScienceDaily. www.sciencedaily.com/releases/2018/06/180620150123.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES